COUNSELLING FOR WOMEN WITH HEREDITARY RISKS OF BREAST NCER: A GUIDE FOR BREAST SURGEONS
Keywords:
Breast câncer, Genetic counsellingAbstract
The hereditary predisposition to breast tumors is responsible for 5% to 10% of ali
cases of this neoplasia. Most of these cases is due recently to the mutations in two
genes denominated BRCA-1 and BRCA-2. However, in spite of the low incidence of
these tumors, cumulative risk of these women and their relatives for developing breast
carcinomas and ovary malign neoplasia it is higher than the general population. Through
an appropriate couselling we can identify women with high risk of inheriting this
susceptibility, and give them further orientation. By molecular tests available, today
it's possibly, to stratify their risk more precisely. Recent development of chemoprevention
of mammary tumors will in the future modulate this risk pharmacologically for those
women's benefit. This present study discuss the basis of the genetic predisposition,
couselling and the alternatives for the prevention of breast câncer in these patients.
Downloads
References
1.BELLER U, HALLER D, CATANE R. KAUFMAN
B, HORNREICH G, LEVY EL. High frequency of
BRCA-1 and BRCA-2 germ-line mutations in
Ashkenazi Jewish ovarian câncer, patients regardless
of family history. Gynecol Oncol 1997; 67: 123-6.
2.BRUGAROLAS J, JACKS T. Double indemnity:
p53, BRCA and câncer. p53 mutation partially
rescues developmental arrest in BRCA-1 and
BRCA-2 null mice, suggesting a role for familial
breast câncer genes in DNA damage repair. Nat
Med 1997; 3: 721-2.
3.CLAUS EB, RISCH N, THOMPSON D. Autosomal
dominant inheritance of early-onset breast câncer.
Câncer 1994; 73: 643-51.
4.CORNELISSE CJ. CORNELIS RS, DEVILEE P.
Genes responsible for familial breast câncer. Pathol
Res Pract 1996; 192: 7, 684-93.
5.COUCH FJ, DESHANO ML, BLACKWOOD A et
al. BRCA-1 mutations in women attending clinicsthat evaluate the risk of breast câncer. N Engl J
Med 1997; 336: 1409-15
6.CUMMINGS SR. NORTON L. ECKERT S et al.
Raloxifene reduces the risk of breast câncer and
may decrease the risk of endometrial câncer in postmenopausal women. Two-year findings from the
multiple outcomes of raloxifene evaluation (more)
trial IN ASCO: Proc Ann Meet. 1998; Abst. 3.
7.EARLY BREAST CÂNCER TRIALISTS'
COLLABORATIVE GROUR Tamoxifen forearly
breast câncer: an overview of the randomised
trials. Lancet 1998; 351: 1451-67.
8.GAIL MH, BRINTON LA, BYAR DP et al.
Projecting individualized probabilities of developing
breast câncer for the white females who are being
examined annually. J Natl Câncer Inst 1989; 81:
1879-86.
9.HABER AD, FEARON ER. The promise of câncer
genetics. Lancet 1998; 351: 1-8.
10.HAKANSSON S, JOHANNSSON O. JOHANSSON U et al. A moderate frequency of BRCA-1
and BRCA-2 germ-line mutations in Scandinavian
familial breast câncer. Am J Hum Genet 1997; 60:
1068-78.
11.HARTMANN L. JENKINS R, SCHAID D, YANG
P. Prophylactic mastectomy (PM): Preliminary
retrospective cohort analysis. Proc Annu Meet Am
Assoc Câncer Res 1987; 38: Al 123.
12.HONG WK. Molecular target for chemoprevention. In: ASCO educational book. Los Angeles:
Thirty-Fourth Ann Meet. 1998; 4-7.
13.HOSKINS KF, STOPFER JE, CALZONE KA et
al. Assessment and counselling for women with a
family history of breast câncer: a guide for
clinicians. JAMA 1995; 273: 577-85.
14.KRAINER M. ARRIETA SS, FITZGERAL MG et
al. Differential contributions of BRCA-1 and BRCA2 to early-onset breast câncer. N Engl J Med 1997;
336: 1416-21.
15.MIKIY, SWENSER J. SHATTUCK-EIDENS D. A
strong candidate for the breast and ovarian câncer
susceptibility BRCA-1. Science 1994; 266: 66-71.
16.OFFIT K. Statement of the American Socity of
Clinicai Oncology: genetic testing for câncer
susceptibility. J Clin Oncol 1996; 145: 1730-6.
17.OFFIT K. Câncer as a genetic disorder. In: Clinicai
câncer genetics risk couselling management. New
York: Wiley-Liss. 1998; 39-65.
18.OFFIT K. The common hereditary cancers. In:
Clinicai câncer genetics risk counseling management. New York: Wiley-Liss. 1998; 66-110.
19.OFFIT K. Quantitative methods. In: Câncer risk
assessment in clinicai câncer genetics risk counselling
e management. New York: Wiley-Liss. 1998; 212-39.
20.ORMISTON W. Hereditary breast câncer. Eur J
Câncer Care 1996; 5: 13-20.
21.PATEL RK, TRIVEDI AH, ARORA DC,
BHATAVDEKAR JM, PATEL DD. DNA repair
proficiency in breast câncer patients and their firstdegree ralatives. Int J Câncer 1997; 73: 20-4.
22.SCHRAG D, KUNTZ KM, GARBER JE,
WEEKS JC. Decision analysis - efects of
prophylactic mastectomy and oophorectomy on
life expectancy among women with BRCA-1 or
BRCA-2 mutations. N Engl Med 1997; 336:
1465-71.
23.STRUEWING JP. WASTSON DF. PONDER BA,
LYNNCH HT, TUCKER MA. Prophylactic
oophorectomy in inherited breast/ovarian câncer
families. J Natl Câncer Inst Monogr 1995; 17:
33-5.
24.STRUEWING JP. HARTGE P, WACHOLDER S et
al. The risk of câncer associated with specific mutations of BRCA-1 and BRCA-2 among Ashkenazi
Jewish. N Engl J Med 1997; 336: 1401-8.
25.WEBERBL. Update on breast câncer susceptibility
genes. In: ASCO educational book. Los Angeles:
Thirty-Fourth Ann Meet. 1998; 242-8.
26.WICKEERHAM DL. COSTANTINO JC,
FISCHER B et al. The initial results from NSAB
protocol P-1: a clinicai trial to determine the worth
of tamoxifen for preventing breast câncer in
women at increased risk. In: ASCO: Proc Ann
Meet. 1998; Abst. 3A.
27.WOOD WC. The role of prophylactic. In: ASCO
educational book. Los Angeles: Thirty-Fourth. Ann
Meet. 1998; 249-51.
28.WOOSTER R, BIGNELL G, LANCASTER J.
Identification os the breast câncer susceptibility
gene BRCA-2. Nature 1995; 378: 789-92.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Auro Del Giglio, Israel Bendit, Alfredo Barros
This work is licensed under a Creative Commons Attribution 4.0 International License.
